Guest Editor(s)
-
- Dr. Sharanjot Saini
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.
Website | E-mail
Special Issue Introduction
Prostate cancer is the second leading cause of death among men with most of the mortality resulting from aggressive disease. Increasing evidence suggests that prostate cancer transcriptome is highly heterogeneous, with RNAs playing a fundamental role in the etiology of prostate cancer. Classes of RNAs include coding and non-coding RNAs (such as micoRNAs (miRNAs), long-non-coding RNAs (lncRNAs) and circular RNAs). These RNAs have intriguing properties with important regulatory functions in prostate cancer and have been implicated in initiation, progression and metastasis via their gene regulatory roles. Similarly, RNAs have been implicated in renal cell carcinoma (RCC), the most prevalent form of kidney cancer. Clinically, RNAs are promising biomarkers and therapeutic targets in prostate and renal cancers. Recent work has evaluated the clinical applications of RNAs in liquid biopsies of these cancers. Furthermore, recent technological advances such as spatial transcriptomics and ability to study RNA-protein interactions have opened up exciting new avenues for RNA research. In addition, recent work has evaluated the clinical applications of these RNAs in RNA-based therapies for these malignancies. In this review, we summarize recent findings on RNAs in prostate cancer and renal cell carcinoma and highlight their potential clinical utility as novel biomarkers and therapeutic targets.
Keywords
RNA, prostate cancer, renal cell carcinoma, spatial transcriptomics, RNA-protein interactions, therapeutic targets
Submission Deadline
31 Jul 2022
Journal of Translational Genetics and Genomics
